D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, pp.177-182, 1987.
DOI : 10.1126/science.3798106

D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, vol.244, issue.4905, pp.707-719, 1989.
DOI : 10.1126/science.2470152

M. Dowsett, J. Bartlett, I. Ellis, J. Salter, M. Hills et al., Correlation between immunohistochemistry (HercepTest) and fluorescencein situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres, The Journal of Pathology, vol.94, issue.4, pp.418-441, 2003.
DOI : 10.1002/path.1313

N. Dendukuri, K. Khetani, M. Mcisaac, and J. Brophy, Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis, Canadian Medical Association Journal, vol.176, issue.10, pp.1429-1463, 2007.
DOI : 10.1503/cmaj.061011

E. Romond, E. Perez, J. Bryant, V. Suman, and C. Geyer, Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1673-84, 2005.
DOI : 10.1056/NEJMoa052122

M. Piccart-gebhart, M. Procter, L. , B. Goldhirsch, A. Untch et al., Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1659-72, 2005.
DOI : 10.1056/NEJMoa052306

M. Bilous, M. Dowsett, W. Hanna, J. Isola, A. Lebeau et al., Current Perspectives on HER2 Testing: A Review of National Testing Guidelines, Modern Pathology, vol.16, issue.2, pp.173-82, 2003.
DOI : 10.1097/01.MP.0000052102.90815.82

H. Yaziji, L. Goldstein, T. Barry, R. Werling, H. Hwang et al., HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods, JAMA, vol.291, issue.16, pp.1972-1979, 2004.
DOI : 10.1001/jama.291.16.1972

J. Bartlett, I. Ellis, M. Dowsett, E. Mallon, D. Cameron et al., Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) ???Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy, Journal of Clinical Oncology, vol.25, issue.28, pp.4423-4430, 2007.
DOI : 10.1200/JCO.2007.11.0973

E. Perez, V. Suman, N. Davidson, S. Marino, P. Kaufman et al., Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial, Journal of Clinical Oncology, vol.24, issue.19, pp.3032-3038, 2006.
DOI : 10.1200/JCO.2005.03.4744

S. Paik, J. Bryant, E. Tan-chiu, E. Romond, W. Hiller et al., Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience, JNCI Journal of the National Cancer Institute, vol.94, issue.11, pp.852-854, 2002.
DOI : 10.1093/jnci/94.11.852